The American Cancer Society estimates approximately 268,490 new prostate cancer cases in the United States for 2022 alone—underscoring the significance of treatment innovations. When multiplied globally, prostate cancer remains one of the most prevalent malignancies affecting men, with incidence rates varying dramatically by region, from 73.7 per 100,000 men in Northern America to 21.8 per 100,000 in Eastern Asia.
Given these staggering case numbers, advances in perioperative treatment strategies carry profound public health implications. New evidence suggesting improved outcomes through integrated systemic and local therapy could potentially benefit hundreds of thousands of patients worldwide. The potential impact on cure rates and quality of life outcomes makes this shift in clinical practice essential for oncologists and patients alike.
Read the full article on GMJ Newsroom.
Was this article helpful?
